A clinical trial to study the effects of Ralfinamide in patients with chronic neuropathic low back pain.
Scientific Title of Study
EFFICACY AND SAFETY OF TWO FIXED DOSES (160 OR 320 MG/DAY) OF RALFINAMIDE IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN. A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED 12-WEEK STUDY WITH LONG-TERM EXTENSION.
Trial Acronym
Secondary IDs if Any
Secondary ID
Identifier
NW-1029/01-08
Other
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
Name
Dr Rakesh Chugh
Designation
Affiliation
Address
CliniRx Research Pvt Ltd, Plot No. 521, Phase III, Udyog Vihar
Gurgaon HARYANA 122016 India
Phone
01244559600
Fax
01244104203
Email
rchugh@clinirx.com
Details of Contact Person Scientific Query
Name
Dr Rakesh Chugh
Designation
Affiliation
CliniRx Research Pvt Ltd
Address
CliniRx Research Pvt Ltd, Plot No. 521, Phase III, Udyog Vihar
Gurgaon HARYANA 122016 India
Phone
01244559600
Fax
01244104203
Email
rchugh@clinirx.com
Details of Contact Person Public Query
Name
Dr Rakesh Chugh
Designation
Affiliation
Address
CliniRx Research Pvt Ltd, Plot No. 521, Phase III, Udyog Vihar
Gurgaon HARYANA 122016 India
Phone
01244559600
Fax
01244104203
Email
rchugh@clinirx.com
Source of Monetary or Material Support
Newron Pharmaceuticals S.p.A.
Primary Sponsor
Name
Newron Pharmaceuticals S.p.A.
Address
Type of Sponsor
Details of Secondary Sponsor
Name
Address
NIL
Countries of Recruitment
India
Sites of Study
No of Sites = 21
Name of Principal
Investigator
Name of Site
Site Address
Phone/Fax/Email
Dr.Subashini Prabhakar
Apollo Hospitals, Hyderabad
Department of Neurology, c/o. Spectra clinical research center, Apollo Hospital, Jubilee Hill, ,-500033 Hyderabad ANDHRA PRADESH
Deenanath Mangeshkar Hospital and Research Center, Pune
Submittted/Under Review
Indraprastha Apollo Hospital, Delhi
Approved
JSS Hospital, Mysore
Submittted/Under Review
Kovai Medical Centre and Hospital, Coimbatore
Approved
M.S.Ramaiah Memorial Hospital, Bangalore
Approved
Mallikatta Neuro and Research Centre, Mangalore
Approved
Neuro Care Centre, Lucknow
Approved
Neurology Centre , Ahemdabad
Approved
Nizams Institute of Medical Sceinces, Hyderabad
Approved
Owasis Hospital & Research Center, Hyderabad
Submittted/Under Review
Ruby General Hospital, Kolkata
Approved
Sir Ganga Ram Hospital, New Delhi
Submittted/Under Review
Sri Ramachandra Medical College, Chennai
Submittted/Under Review
St. John's Medical College & Hospital, Bangalore
Submittted/Under Review
Vijaya Health Centre, Chennai
Submittted/Under Review
Regulatory Clearance Status from DCGI
Status
Approved/Obtained
Health Condition / Problems Studied
Health Type
Condition
Patients
CHRONIC NEUROPATHIC LOW BACK PAIN,
Intervention / Comparator Agent
Type
Name
Details
Comparator Agent
Placebo
NA, Daily
Intervention
Ralfinamide
160-320 mg, Daily
Inclusion Criteria
Age From
Age To
Gender
Details
1. Patient presents in the physical/neurological examination with low back pain with or without radiation into the lower limb that must display a topography compatible with the L1 to S1 territory and/or respective sensory or motoric impairments.
2. Patient must have chronic neuropathic low back pain with a minimum intensity of ?40 mm? (moderate) or greater on the Visual Analogue Scale (VAS; 100-mm) at screening, and an average of ?40 mm? or more at baseline (based on prior 7 days).
3. The onset of pain has occurred at least three months, but not longer than 3 years, prior to the screening visit, as assessed by the investigator in the patient?s medical history.
4. Patient is affected by current neuropathic pain (pain provoked by a lesion of the peripheral nervous system). The diagnosis should be made by a neurologist/anaesthesiologist/pain specialist and based on history, clinical evaluation and/or laboratory findings (rule out systemic cause, e.g., hypothyroidism, rheumatoid arthritis, nephropathy, diabetes [MNSI score >2]) in accordance with the taxonomy of the diagnostic criteria documented in the International Association for the Study of Pain (IASP) Classification of Chronic Pain. A neurological disease must be directly correlated with pain, including pain due to spinal root compression.
If radiologic data supporting the diagnosis had been obtained previously it should be documented in the patient?s records. In case radiologic examinations are not available, the Investigator should consider performing these examinations, if necessary to support the diagnosis, during the screening phase.
5. Patient has one of the following causes of neuropathic low back pain: Non-cancer lumbar pain due to compression radiculopathy or post-traumatic/post-surgical lumbar radiculopathy.
6. Patient?s low back pain has a clear neuropathic component, as indicated by a rating on the Pain Detect Questionnaire (PD-Q) of greater than 18.
7. Patient is 18-85 years of age, inclusive.
8. Patient is willing and able to understand and sign an approved Informed Consent Form.
ExclusionCriteria
Details
1. Females who are pregnant or lactating, or of childbearing potential, defined as follows: surgically sterilized for less than one year; aged ≥ 50 years and post-menopausal condition started less than 24 months prior to the screening visit; or aged < 50 years and post-menopausal condition started less than 24 months prior, and/or post-menopausal status has not been confirmed by determination of the serum levels of FSH and 17-β estradiol; or fecund and not practicing double contraception method (e.g., hormonal contraceptive plus barrier method).
2. Patients with any other cause of peripheral or central neuropathic pain (including psychogenic and nociceptive pain), pain due to metabolic (including diabetes; MNSI score > 2) infectious or proliferative diseases, or pain due to any condition that is as severe as the neuropathic pain.
3. Patients with a history of migrating pain and former mononeuropathy or neuralgias in other anatomical territories.
4. Based on medical history or ophthalmological examination, patient has one of the following conditions:
? is albino
? family history of hereditary retinal disease
? progressive and/or severe diminution of visual acuity, i.e. 20/70
? retinitis pigmentosa
? retinal pigmentation due to any cause
? any active retinopathy or ocular inflammation (uveitis),
? severe diabetic retinopathy, or
? moderate proliferative retinopathy.
5. Patients with severe trophic changes, severe swelling, joint deformities or stiff joint with limited passive movement, or patients who may be candidates for back surgery within 52 weeks after baseline.
6. History or current diagnosis of positive test for Hepatitis B or C (unless vaccinated).
7. Clinically significant, uncontrolled gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease (including non well-controlled hypertension), asthma, uncompensated chronic obstructive pulmonary disease (COPD), severe uncontrolled diabetes (HbA1c > 10.0).
8. Second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, significant ECG abnormalities or QTc ≥ 450 msec (males) or ≥ 470 msec (females), where QTc is based on Bazett?s correction method.
9. Concomitant disease likely to interfere with the study drug (e.g. capable of altering absorption, metabolism or elimination of drugs).
10. History of psychosis (e.g. schizophrenia or psychotic depression) or any current DSM-IV Axis I diagnosis including dementia, depression (BDI > 13), psychosis, anxiety disorders, mental retardation, etc.
11. Neoplastic disorder which is either active or has been in remission for less than one year.
12. History or concomitant diagnosis of seizure disorder, or severe dizziness or fainting on standing due to postural hypotension.
13. History of allergic response, hypersensitivity or contraindications to anticonvulsant drugs or MAO-B inhibitors, history of prior drug interactions, or past characterisation as a ?slow metaboliser?.
14. Treatment with potentially hepatotoxic (e.g., tamoxifen), nephrotoxic, or antineoplastic drugs within the past the 6 months, depot neuroleptics in the previous 6 months, or oral neuroleptics in the 30 days prior to randomisation.
15. Patients who participated in prior trials with ralfinamide or received any investigational drug or device within 30 days prior to randomisation or 5 half-lives, whichever is longer. Use of an investigational drug or device other than ralfinamide during the study is not permitted.
16. Treatment with guanethidine or other sympathetic blockers in the 3 months prior to randomisation. Use of β-blockers for an indication other than pain will be permitted, provided they are given at a stable dose for at least one month prior to screening.
17. Treatment within 4 weeks preceding randomisation with any of the following: drugs known to significantly inhibit or induce enzymes (e.g., barbiturates, phenothiazines, etc.), opioids, tri- or tetra-cyclic antidepressants, SNRIs (e.g., venlafaxine, duloxetine), MAO inhibitors (e.g., selegiline), tramadol, dextromethorphan, meperidine derivatives, neuro-stimulating devices, such as spinal cord stimulation (SCS), transcutaneous electrical nerve stimulation (TENS) or peripheral nerve stimulation (PNS), acupuncture, homeopathic remedies for pain or any kind of surgical treatment or blockade for the pain. Treatment with SSRIs, NSAIDs (including COX-inhibitors) and minor analgesics (e.g., paracetamol) will be permitted if taken at a stable dose from at least 4 weeks prior to study start (screening), provided that the dose will not be changed during the study.
18. Treatment with antiepileptic drugs (AEDs, e.g. pregabalin, gabapentin, carbamazepine, etc.), benzodiazepines (except if used as hypnotic at a stable dose), mexiletine, skeletal muscle relaxants, steroids (except if used for allergies, asthma, etc. and maintained at a stable dose), capsaicin, coumarin anticoagulants, topical analgesics or injection of local anesthetics in the 2 weeks prior to randomisation.
19. Any abnormality that the investigator deems to be clinically relevant, either on medical history, physical examination, ECG, or diagnostic laboratory test, especially ASAT (SGOT), ALAT (SGPT), γGT or bilirubin, during the screening period, greater than the upper limit of normal (ULN). Patients whose test results are normal on repeat examination (Day -4) would be eligible for the study.
20. In the judgment of the Investigator, the subject is likely to be noncompliant or uncooperative during the study.
Method of Generating Random Sequence
Computer generated randomization
Method of Concealment
Centralized
Blinding/Masking
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
Primary Outcome
Outcome
TimePoints
The efficacy of ralfinamide will be based on the mean change from baseline to Week 12 or endpoint (in case of premature termination) on the 11-point Likert categorical scale (daily pain assessment).
The efficacy of ralfinamide will be based on the mean change from baseline to Week 12 or endpoint (in case of premature termination) on the 11-point Likert categorical scale (daily pain assessment).
Secondary Outcome
Outcome
TimePoints
? ?Responder? rates, based on the proportion of patients experiencing a 30% or a 50% improvement from baseline to endpoint in mean pain rating on the 11-point Likert scale (daily pain assessment),
? Change from baseline in the subject?s perception of of the impact of pain on sleep and activity (11-point Likert scales),
? Change from baseline in the Visual Analogue Scale (VAS; 100-mm), as rated by the patient,
? Time to first use and cumulative number of days of usage of rescue pain medication.
? ?Responder? rates, based on the proportion of patients experiencing a 30% or a 50% improvement from baseline to endpoint in mean pain rating on the 11-point Likert scale (daily pain assessment),
? Change from baseline in the subject?s perception of of the impact of pain on sleep and activity (11-point Likert scales),
? Change from baseline in the Visual Analogue Scale (VAS; 100-mm), as rated by the patient,
? Time to first use and cumulative number of days of usage of rescue pain medication.
Target Sample Size
Total Sample Size="0" Sample Size from India="" Final Enrollment numbers achieved (Total)= "" Final Enrollment numbers achieved (India)=""